Douglas “Doug” Langa was appointed Senior Vice President, Head of
North America Operations and President of Novo Nordisk Inc. in March
2017 and was promoted to Executive Vice President, North America
Operations and President of Novo Nordisk Inc. in August 2017. In this
role, Doug has full business responsibility for Novo Nordisk’s largest
sales region, comprised of the United States and Canada.
Prior to his current role, Doug served as Senior Vice President,
Market Access, where he was responsible for securing formulary access
with key payer customers for Novo Nordisk brands. The Market Access
function at Novo Nordisk covers payer marketing, contract strategy,
pricing, and account management for all promoted and in-line brands.
Under Doug’s leadership, the Market Access account executive team has
received numerous third-party recognitions for their performance
allowing a broad number of patients with chronic diseases to benefit
from having access to Novo Nordisk brands.
Doug previously served as Corporate Vice President, Market Access.
He joined Novo Nordisk in 2011 as the Senior Director, Managed
Markets, in which he was responsible for strategy development and
execution across Novo Nordisk’s diabetes portfolio.
Doug joined Novo Nordisk from GlaxoSmithKline (GSK), where he was
the Senior Director of Payer Marketing. Prior to GSK, he spent the
majority of his career at Johnson and Johnson, where he held various
roles of increasing responsibility within Managed Markets, Sales
Leadership, and Marketing. He has over 25 years of experience in the
pharmaceutical and medical device industry.
Doug graduated from Widener University, earned his MBA from Fordham
University, and holds professional certificates from The Wharton
School and Harvard Business School.